TI
CDTX

Turner Investments’s Cidara Therapeutics CDTX Stock Holding History

Turner Investments’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,473
Closed -$306K – 226
2016
Q4 		$306K Buy
1,473
+100
+7% +$20.8K 0.12% 192
2016
Q3 		$314K Hold
1,373
– – 0.1% 159
2016
Q2 		$283K Buy
+1,373
New +$332K 0.09% 169

Other funds holding CDTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Turner Investments's CDTX Position: Q1 2017 in Review

Turner Investments sold out of Cidara Therapeutics (CDTX) in Q1 2017, closing a stake of 1,473 shares — an estimated $306K sold.

Turner Investments first reported a position in CDTX in Q2 2016 and held it in 3 quarters. The position peaked at $314K in Q3 2016. 54 funds tracked by Wall St. Rank hold CDTX as of Q1 2017.

  • Turner Investments reported no remaining Cidara Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Turner Investments sold 1,473 Cidara Therapeutics shares in Q1 2017, an estimated $306K.
  • Turner Investments first reported a position in Cidara Therapeutics in Q2 2016 and held it in 3 quarters.
  • Turner Investments's Cidara Therapeutics position peaked at $314K in Q3 2016.
  • 54 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2017.

Based on Turner Investments's 13F filing for Q1 2017, filed 11 May 2017.